Breast Cancer Market 2018 - Global Industry Size, Shares, Trends, Growth, Analysis and Forecast 2022

Researchmoz added Most up-to-date research on " Global Breast Cancer Market: Industry Analysis & Outlook (2018-2022)" to its huge collection of research reports.

‘Breast cancer’ defines a malignant tumor that has developed from cells in the breast. Some breast cancers are called in situ as they are confined within the ducts (ductal carcinoma in situ or DCIS) or lobules (lobular carcinoma in situ or LCIS) where they originated. Although, less commonly, breast cancer can also instigate in the stromal tissues, which includes the fatty and fibrous connective tissues of the breast. In the early stages, breast cancer may not cause any symptoms. A lump may be too small to feel or to cause any unusual changes that could be noticed on own. Typically, an abnormal area shows up on a screening mammogram which leads to further testing. Several risk factors including smoking and alcohol consumption, exposure to estrogen, gender, age, family history and personal history are linked to the growth of breast cancer.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1692365

The global breast cancer market is likely to grow strongly in the coming years driven by rising healthcare expenditure, rising diabetic and obese population, increasing consumption of alcohol and tobacco and rising female population above 65 years of age. Key trends of the market includes rising development of PARP inhibitors, increasing adoption of minimally invasive procedures and rising awareness programs and research grants. However, growth of the market can be hindered by several factors including financial burden of breast cancer, drug development challenges in developing countries, long term side effects of drugs.

The report “Global Breast Cancer Market: Industry Analysis & Outlook (2018-2022)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the US, Europe and APAC regions along with the global market. The report profiles the key players of the market including Johnson & Johnson, AbbVie, AstraZeneca and Roche.

Table of Content

1. Introduction
1.1 Breast Cancer
1.2 Types
1.3 Stages
1.4 Risk Factors
1.4 Symptoms & Diagnosis
1.5 Treatment

2. Global Breast Cancer Market
2.1 Global Breast Cancer Market by Value
2.2 Global Breast Cancer Market Forecast by Value
2.3 Global Breast Cancer Market by Region
2.4 Global Breast Cancer Drug Development by Stages

Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/global-breast-cancer-market-industry-analysis-outlook-20182022-report.html/toc

3. Regional Breast Cancer Market Analysis
3.1 The U.S.
3.1.1 The U.S. Breast Cancer Market by Value
3.1.2 The U.S. Breast Cancer Market Forecast by Value
3.1.3 The U.S. Breast Cancer Market by Addressable Population
3.1.4 The U.S. Breast Cancer Market Forecast by Addressable Population
3.1.5 The U.S. Breast Cancer Population by Age
3.1.6 The US HER2+ Node Positive Breast Cancer Patients Volume
3.1.7 The US HER2+ Node Negative Breast Cancer Patients Volume
3.1.8 The US HER2+ Node Negative (High Risk) Breast Cancer Patients Volume
3.2 Europe
3.2.1 EU5 Breast Cancer Market by Value
3.2.2 EU5 Breast Cancer Market Forecast by Value
3.2.3 Europe HER2+ Node Positive Breast Cancer Patients Volume
3.2.4 Europe HER2+ Node Negative Breast Cancer Patients Volume
3.2.5 Europe HER2+ Node Negative (High Risk) Breast Cancer Patients Volume
3.3 APAC
3.3.1 APAC Breast Cancer Market by Value
3.3.2 APAC Breast Cancer Market Forecast by Value
3.3.3 APAC Breast Cancer Market by Countries
3.3.4 Japan’s Breast Cancer Market by Value
3.3.5 Japan’s Breast Cancer Market Forecast by Value
3.3.6 China’s Breast Cancer Market by Value
3.3.7 China’s Breast Cancer Market Forecast by Value
3.3.8 Australia’s Breast Cancer Market by Value
3.3.9 Australia’s Breast Cancer Market Forecast by Value

4. Market Dynamics
4.1 Growth Drivers
4.1.1 Rising Consumption of Tobacco and Alcohol
4.1.2 Increasing Global Diabetic Population
4.1.3 Accelerating Obese Population
4.1.4 Increasing Healthcare Expenditure Per Capita
4.1.5 Rising Female Population Aged 65 Years & Above
4.2 Key Trends & Developments
4.2.1 PARP Inhibitors under Development
4.2.32Rising Adoption of Minimally Invasive Procedures
4.2.3 Increasing Awareness Programs and Research Grants
4.3 Challenges
4.3.1 Financial Burden of Breast Cancer
4.3.2 Drug Development Challenges in Developing Countries
4.3.3 Long Term Side Effects

5. Competition
5.1 Global Market
5.1.1 Revenue Comparison by Company
5.1.2 R&D Expenditure Comparison by Company
5.1.3 Market Cap Comparison by Company

Continue...

Global Breast Cancer Market: Industry Analysis & Outlook (2017-2021) - Johnson & Johnson, AstraZeneca, AbbVie, Roche

Researchmoz added Most up-to-date research on "Global Breast Cancer Market: Industry Analysis & Outlook (2017-2021)" to its huge collection of research reports.

Breast cancer’ defines a malignant tumor that has developed from cells in the breast. Some breast cancers are called in situ as they are confined within the ducts (ductal carcinoma in situ or DCIS) or lobules (lobular carcinoma in situ or LCIS) where they originated. Although, less commonly, breast cancer can also instigate in the stromal tissues, which include the fatty and fibrous connective tissues of the breast. In the early stages, breast cancer may not cause any symptoms. A lump may be too small to feel or to cause any unusual changes that could be noticed on own. Typically, an abnormal area shows up on a screening mammogram which leads to further testing. Several risk factors including smoking and alcohol consumption, exposure to estrogen, gender, age, radiation therapy, family history and personal history are linked to the growth of breast cancer.

The global market for breast cancer has grown swiftly over the past few years driven by introduction of several new drugs and biosimilars. The overall breast cancer market remained mainly dominated by the generic drugs. The future market for breast cancer will grow in the coming years as there exist unmet need for new drugs that would overcome resistance and prevent recurrence of the disease.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=964493

The global breast cancer market is likely to grow strongly in the coming years driven by rising healthcare expenditure, rising diabetic and obese population, increased spending on medicines, increasing consumption of alcohol and tobacco and rising female population above 65 years of age. Key trends of the market includes rising development of PARP inhibitors, clinical trials of CDK4/6 inhibitors and introduction of new imaging tests. However, growth of the market can be hindered by several factors including drug development challenges in developing countries, long term side effects of drugs and heavy costs associated with drug development.

The report “Global Breast Cancer Market: Industry Analysis & Outlook (2017-2021)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S., Europe and APAC regions along with the global market. The report profiles the key players of the market including Johnson & Johnson, AbbVie, AstraZeneca and Roche.

Table of Content

1. Introduction1.1 Market Overview

2. Global Breast Cancer Market
2.1 Global Breast Cancer Market by Value
2.2 Global Breast Cancer Market Forecast by Value
2.3 Global Breast Cancer Market by Region
2.4 Global Breast Cancer Drug Development by Stages

3. Regional Breast Cancer Market
3.1 The U.S.
3.1.1 The U.S. Breast Cancer Market by Value
3.1.2 The U.S. Breast Cancer Market Forecast by Value
3.1.3 The U.S. Breast Cancer Market by Addressable Population
3.1.4 The U.S. Breast Cancer Market Forecast by Addressable Population
3.1.5 The U.S. Breast Cancer Population by Age
3.2 Europe
3.2.1 EU5 Breast Cancer Market by Value
3.2.2 EU5 Breast Cancer Market Forecast by Value
3.3 APAC
3.3.1 APAC Breast Cancer Market by Value
3.3.2 APAC Breast Cancer Market Forecast by Value
3.3.3 APAC Breast Cancer Market by Countries
3.3.4 Japan’s Breast Cancer Market by Value
3.3.5 Japan’s Breast Cancer Market Forecast by Value
3.3.6 China’s Breast Cancer Market by Value
3.3.7 China’s Breast Cancer Market Forecast by Value
3.3.8 Australia’s Breast Cancer Market by Value
3.3.9 Australia’s Breast Cancer Market Forecast by Value

4. Market Dynamics
4.1 Growth Drivers
4.1.1 Rising Consumption of Tobacco and Alcohol
4.1.2 Increasing Global Diabetic Population
4.1.3 Increasing Obesity
4.1.4 Increasing Healthcare Expenditure Per Capita
4.1.5 Rising Female Population Aged 65 Years & Above
4.1.6 Global Spending on Medicines
4.2 Key Trends & Developments
4.2.1 PARP Inhibitors under Development
4.2.2 CDK4/6 Inhibitors Under Clinical Trials for Breast Cancer
4.2.3 Introduction of Newer Imaging Tests
4.3 Challenges
4.3.1 Long Term Side Effects
4.3.2 Drug Development Challenges in Developing Countries
4.3.3 Heavy Drug Developmental Costs

5. Competition
5.1 Revenue Comparison
5.2 Research & Development Expenditure Comparison
5.3 Market Cap Comparison

6. Company Profiles
6.1 Johnson & Johnson
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 AstraZeneca
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 AbbVie
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Roche
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies

Browse Detail Report With TOC @ https://www.researchmoz.us/global-breast-cancer-market-industry-analysis-outlook-20172021-report.html

Global Breast Cancer Industry Key Trends, Size, Growth, Shares And Forecast Research Report 2015

Researchmoz added Most up-to-date research on "Global Breast Cancer Market Report: 2015 Edition" to its huge collection of research reports.

Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women. Breast cancer knows no boundaries be it age, gender, socioeconomic status or geographic location. The most common risk factors for breast cancer are being female and growing older.

In the past few years, the cases of breast cancer have increased tremendously in regions like the US and the Europe. The breast cancer market is driven by various factors like aging female population, obesity and diabetes, dense breast tissues, healthcare expenditure, exposure to X-Ray and Gamma Radiations, Estrogen-Progestin Therapy (EPT) and increased consumption of alcohol and tobacco. A major trend which will probably remain eternally in the breast cancer treatment industry is the fact that novel and innovative technologies and pharmaceutical molecules are always under development. Challenges associated with breast cancer are like, financial burdens associated with the treatment and adverse effects of Aromatase Inhibitors (AI) on patients.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=315089

The market for breast cancer drugs represents an area of potential opportunity in both developed and developing countries. Due to effectiveness and advancements in technology, a large number of companies are focusing to develop innovative breast cancer drugs. Further, the companies are forming alliances and agreements to develop effective treatment methods for breast cancer.

The present report provides a comprehensive analysis of the global breast cancer diagnosis and treatment market with focus on regions like the US, Brazil, Europe and APAC Countries. Furthermore, market dynamics such as the industry trends and development, the underlying growth drivers and major issues faced by the industry are elicited. On the contention front, the market is personified by the intense competition in terms of research and development of novel therapeutic molecules. The leading players operating in the industry include Hologic, Johnson and Johnson, Siemens AG, Roche and Novartis which are also profiled in this report.

Table Of Content

1. Market Overview1.1 Breast Cancer
1.2 Types of Breast Cancer
1.3 Risk Factors
1.4 Symptoms of Breast Cancer
1.5 Diagnosis and Treatment of Breast Cancer
1.5.1 Breast Cancer Screening and Diagnostic Measures
1.5.2 Breast Cancer Treatment

2. Breast Cancer Market
2.1 Global Market

- Diagnostics Market
- Therapeutic Market
- Market Segmentation

3. Regional Markets
3.1 The U.S. Breast Cancer Market
3.1.1 The U.S. Breast Cancer Diagnostics Market
3.1.2 The U.S. Breast Cancer Therapeutic Market
3.1.3 The U.S. Metastatic Breast Cancer Market
3.2. Brazilian Breast Cancer Market
3.2.1 Brazilian Breast Cancer Diagnostic Market
3.2.2 Brazilian Breast Cancer Therapeutic Market
3.3 APAC Countries
3.3.1 APAC Diagnostic Market
3.3.2 APAC Therapeutic Market
3.4 European Breast Cancer Market
3.4.1 European Breast Cancer Diagnostic Market
3.4.2 European Metastatic Breast Cancer Market

4. Market Dynamics
4.1 Industry Developments
4.1.1 Introduction of New Drugs & Therapies
4.1.2 Development of Scintimammography for Molecular Breast Imaging
4.1.3 Compounds under Study to Reduce Breast Cancer
4.1.4 Researches on DCIS Prediction
4.2 Growth Drivers
4.2.1 Increasing Use of Tobacco and Alcohol
4.2.2 Increasing Diabetic and Obese Population Worldwide
4.2.3 Rising Healthcare Expenditure
4.2.4 Growing Women Population (Over 45 Years)
4.2.5 Increasing Global Spending on Medicines
4.2.6 Dense Breast Tissue
4.2.7 Exposure to X-Ray and Gamma Radiations
4.2.8 Estrogen-Progestin Therapy (EPT)
4.3 Challenges
4.3.1 Financial Burden of Breast Cancer
4.3.2 Adverse Effects of Aromatase Inhibitors (AI)

5. Competitive Landscape

- Comparison of Drugs
- Net Income
- R&D Budget

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=315089

Global Breast Cancer Market: Industry Analysis & Outlook (2017-2021) | Now Available at Researchmoz.us

Researchmoz added Most up-to-date research on "Global Breast Cancer Market: Industry Analysis & Outlook (2017-2021)" to its huge collection of research reports.

Breast cancer’ defines a malignant tumor that has developed from cells in the breast. Some breast cancers are called in situ as they are confined within the ducts (ductal carcinoma in situ or DCIS) or lobules (lobular carcinoma in situ or LCIS) where they originated. Although, less commonly, breast cancer can also instigate in the stromal tissues, which include the fatty and fibrous connective tissues of the breast. In the early stages, breast cancer may not cause any symptoms. A lump may be too small to feel or to cause any unusual changes that could be noticed on own. Typically, an abnormal area shows up on a screening mammogram which leads to further testing. Several risk factors including smoking and alcohol consumption, exposure to estrogen, gender, age, radiation therapy, family history and personal history are linked to the growth of breast cancer.

The global market for breast cancer has grown swiftly over the past few years driven by introduction of several new drugs and biosimilars. The overall breast cancer market remained mainly dominated by the generic drugs. The future market for breast cancer will grow in the coming years as there exist unmet need for new drugs that would overcome resistance and prevent recurrence of the disease.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=964493

The global breast cancer market is likely to grow strongly in the coming years driven by rising healthcare expenditure, rising diabetic and obese population, increased spending on medicines, increasing consumption of alcohol and tobacco and rising female population above 65 years of age. Key trends of the market includes rising development of PARP inhibitors, clinical trials of CDK4/6 inhibitors and introduction of new imaging tests. However, growth of the market can be hindered by several factors including drug development challenges in developing countries, long term side effects of drugs and heavy costs associated with drug development.

The report “Global Breast Cancer Market: Industry Analysis & Outlook (2017-2021)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S., Europe and APAC regions along with the global market. The report profiles the key players of the market including Johnson & Johnson, AbbVie, AstraZeneca and Roche.

Table of Content

1. Introduction1.1 Market Overview

2. Global Breast Cancer Market
2.1 Global Breast Cancer Market by Value
2.2 Global Breast Cancer Market Forecast by Value
2.3 Global Breast Cancer Market by Region
2.4 Global Breast Cancer Drug Development by Stages

3. Regional Breast Cancer Market
3.1 The U.S.
3.1.1 The U.S. Breast Cancer Market by Value
3.1.2 The U.S. Breast Cancer Market Forecast by Value
3.1.3 The U.S. Breast Cancer Market by Addressable Population
3.1.4 The U.S. Breast Cancer Market Forecast by Addressable Population
3.1.5 The U.S. Breast Cancer Population by Age
3.2 Europe
3.2.1 EU5 Breast Cancer Market by Value
3.2.2 EU5 Breast Cancer Market Forecast by Value
3.3 APAC
3.3.1 APAC Breast Cancer Market by Value
3.3.2 APAC Breast Cancer Market Forecast by Value
3.3.3 APAC Breast Cancer Market by Countries
3.3.4 Japan’s Breast Cancer Market by Value
3.3.5 Japan’s Breast Cancer Market Forecast by Value
3.3.6 China’s Breast Cancer Market by Value
3.3.7 China’s Breast Cancer Market Forecast by Value
3.3.8 Australia’s Breast Cancer Market by Value
3.3.9 Australia’s Breast Cancer Market Forecast by Value

4. Market Dynamics
4.1 Growth Drivers
4.1.1 Rising Consumption of Tobacco and Alcohol
4.1.2 Increasing Global Diabetic Population
4.1.3 Increasing Obesity
4.1.4 Increasing Healthcare Expenditure Per Capita
4.1.5 Rising Female Population Aged 65 Years & Above
4.1.6 Global Spending on Medicines
4.2 Key Trends & Developments
4.2.1 PARP Inhibitors under Development
4.2.2 CDK4/6 Inhibitors Under Clinical Trials for Breast Cancer
4.2.3 Introduction of Newer Imaging Tests
4.3 Challenges
4.3.1 Long Term Side Effects
4.3.2 Drug Development Challenges in Developing Countries
4.3.3 Heavy Drug Developmental Costs

5. Competition
5.1 Revenue Comparison
5.2 Research & Development Expenditure Comparison
5.3 Market Cap Comparison

6. Company Profiles
6.1 Johnson & Johnson
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 AstraZeneca
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 AbbVie
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Roche
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=964493

New Study on Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes

Researchmoz added Most up-to-date research on "Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes" to its huge collection of research reports.

The breast cancer pipeline is the largest in the pharmaceutical industry, with 1,050 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. The degree and proportion of breakthrough innovations in this pipeline is exceptional & GBI Research analysis identified 333 first-in-class programs in the breast cancer pipeline, acting on 251 first-in-class molecular targets. This accounts for some 39% of all products with a disclosed molecular target, and is reflective of the high degree of innovation in this indication. This has far-reaching strategic implications for all market participants, as despite the high attrition rate in breast cancer, it is highly likely many of the first-in-class products will reach the market over the coming decade and, will have the opportunity to transform the clinical and commercial landscape.

Potential driving factors behind this market include a very large and growing patient pool, a well-established disease market with a number of strong unmet needs, and the strong understanding of the disease pathophysiology that has developed over the last decade, facilitating the development of novel compounds that may fill the unmet needs.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=668359

Some 289 first-in-class products that are currently in development have not yet been involved in licensing or co-development deals, meaning there are numerous opportunities for in-licensing or co-development in this indication, which already has a strong track record of breakthrough innovation yielding highly commercially and clinically successful therapies.

Scope

- The report analyzes innovation in breast cancer, in the context of the overall pipeline and current market landscape. In addition, it analyzes the deals landscape surrounding first-in-class products in breast cancer, and pinpoints opportunities for in-licensing.
- A brief introduction to breast cancer, including symptoms, pathophysiology, and an overview of pharmacotherapy and treatment algorithms.
- The changing molecular target landscape between the market and the pipeline, and particular focal points of innovation in the pipeline.
- Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target.
- Identification and assessment of first-in-class molecular targets, with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets.
- Assessment of the licensing and co-development deal landscape for breast cancer therapies, and benchmarking of deals involving first-in-class versus non-first-in-class-products.

Reasons to buy

- Understand the current clinical and commercial landscape, including a comprehensive study of disease pathogenesis, diagnosis, prognosis and the available treatment options available at each stage of diagnosis.
- Visualize the composition of the breast cancer market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of the gaps in the current market.
- Analyze the breast cancer pipeline, stratified by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
- Identify commercial opportunities in the breast cancer deals landscape by analyzing trends in licensing and co-development deals, and producing a list of breast cancer therapies that are not yet involved in deals and may be potential investment opportunities.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=668359

Global Breast Cancer Industry Trend, Growth, Analysis & Outlook (2017-2021) | New Release

Researchmoz added Most up-to-date research on "Global Breast Cancer Market: Industry Analysis & Outlook (2017-2021)" to its huge collection of research reports.

Breast cancer’ defines a malignant tumor that has developed from cells in the breast. Some breast cancers are called in situ as they are confined within the ducts (ductal carcinoma in situ or DCIS) or lobules (lobular carcinoma in situ or LCIS) where they originated. Although, less commonly, breast cancer can also instigate in the stromal tissues, which include the fatty and fibrous connective tissues of the breast. In the early stages, breast cancer may not cause any symptoms. A lump may be too small to feel or to cause any unusual changes that could be noticed on own. Typically, an abnormal area shows up on a screening mammogram which leads to further testing. Several risk factors including smoking and alcohol consumption, exposure to estrogen, gender, age, radiation therapy, family history and personal history are linked to the growth of breast cancer.

The global market for breast cancer has grown swiftly over the past few years driven by introduction of several new drugs and biosimilars. The overall breast cancer market remained mainly dominated by the generic drugs. The future market for breast cancer will grow in the coming years as there exist unmet need for new drugs that would overcome resistance and prevent recurrence of the disease.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=964493

The global breast cancer market is likely to grow strongly in the coming years driven by rising healthcare expenditure, rising diabetic and obese population, increased spending on medicines, increasing consumption of alcohol and tobacco and rising female population above 65 years of age. Key trends of the market includes rising development of PARP inhibitors, clinical trials of CDK4/6 inhibitors and introduction of new imaging tests. However, growth of the market can be hindered by several factors including drug development challenges in developing countries, long term side effects of drugs and heavy costs associated with drug development.

The report “Global Breast Cancer Market: Industry Analysis & Outlook (2017-2021)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S., Europe and APAC regions along with the global market. The report profiles the key players of the market including Johnson & Johnson, AbbVie, AstraZeneca and Roche.

Table of Content

1. Introduction1.1 Market Overview

2. Global Breast Cancer Market
2.1 Global Breast Cancer Market by Value
2.2 Global Breast Cancer Market Forecast by Value
2.3 Global Breast Cancer Market by Region
2.4 Global Breast Cancer Drug Development by Stages

3. Regional Breast Cancer Market
3.1 The U.S.
3.1.1 The U.S. Breast Cancer Market by Value
3.1.2 The U.S. Breast Cancer Market Forecast by Value
3.1.3 The U.S. Breast Cancer Market by Addressable Population
3.1.4 The U.S. Breast Cancer Market Forecast by Addressable Population
3.1.5 The U.S. Breast Cancer Population by Age
3.2 Europe
3.2.1 EU5 Breast Cancer Market by Value
3.2.2 EU5 Breast Cancer Market Forecast by Value
3.3 APAC
3.3.1 APAC Breast Cancer Market by Value
3.3.2 APAC Breast Cancer Market Forecast by Value
3.3.3 APAC Breast Cancer Market by Countries
3.3.4 Japan’s Breast Cancer Market by Value
3.3.5 Japan’s Breast Cancer Market Forecast by Value
3.3.6 China’s Breast Cancer Market by Value
3.3.7 China’s Breast Cancer Market Forecast by Value
3.3.8 Australia’s Breast Cancer Market by Value
3.3.9 Australia’s Breast Cancer Market Forecast by Value

4. Market Dynamics
4.1 Growth Drivers
4.1.1 Rising Consumption of Tobacco and Alcohol
4.1.2 Increasing Global Diabetic Population
4.1.3 Increasing Obesity
4.1.4 Increasing Healthcare Expenditure Per Capita
4.1.5 Rising Female Population Aged 65 Years & Above
4.1.6 Global Spending on Medicines
4.2 Key Trends & Developments
4.2.1 PARP Inhibitors under Development
4.2.2 CDK4/6 Inhibitors Under Clinical Trials for Breast Cancer
4.2.3 Introduction of Newer Imaging Tests
4.3 Challenges
4.3.1 Long Term Side Effects
4.3.2 Drug Development Challenges in Developing Countries
4.3.3 Heavy Drug Developmental Costs

5. Competition
5.1 Revenue Comparison
5.2 Research & Development Expenditure Comparison
5.3 Market Cap Comparison

6. Company Profiles
6.1 Johnson & Johnson
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 AstraZeneca
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 AbbVie
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Roche
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=964493

New Study Reveals Breast Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016 | Researchmoz

Researchmoz added Most up-to-date research on "Breast Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016" to its huge collection of research reports.

Medical Devices sector report, Breast Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016" provides an overview of Breast Cancer Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Breast Cancer Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=885316

Scope

- Extensive coverage of the Breast Cancer Diagnostic Tests under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Breast Cancer Diagnostic Tests and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Breast Cancer Diagnostic Tests under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the products current stage of development, territory and estimated launch date

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=885316

Global Cancer Diagnostic Market with Focus on Lung and Breast Cancer (2016-2020) | Now Available at Researchmoz.us

Researchmoz added Most up-to-date research on "Global Cancer Diagnostic Market with Focus on Lung and Breast Cancer (2016-2020)" to its huge collection of research reports.

The report entitled Global Cancer Diagnostic Market with Focus on Lung and Breast Cancer (2016-2020), provides analysis of the global cancer diagnostics market and the US cancer diagnostics market, with detailed analysis of market size and growth, penetration and market share. The report also provides the analysis of the global and the US cancer market, by prevalence, new cases, deaths, type of cancers, etc. The report provides the market sizing of the global lung and breast cancer diagnostic market by value and by segments.

The report also discusses about the different diagnostic test of lung cancer and breast cancer. The diagnostics test analyzed in the report are: MetaStat (Meta Test) (Breast Cancer Test), OncotypeDX (Breast Cancer Test), OncoCyte (Lung Cancer Test), Veracytes Test (Lung Cancer Test) and Integrated Diagnostics, Inc. Test (Lung Cancer Test).

Country Coverage

North America (US)

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=841071

Executive Summary

A disease caused by abnormal growth of cells in the body, is called Cancer. In this disease, the formation of new cells slows or start dividing, forming lumps. However, all lumps are not cancerous; and this can be known by diagnosis.

There are various types of cancer- prostate cancer, breast cancer, lung and bronchus cancer, colon and rectum cancer, bladder cancer, melanoma of the skin, non-hodgkin lymphoma, kidney and renal, pelvis cancer, thyroid cancer, endometrial cancer and others.

Cancer is diagnosed using various tools, which confirm the presence of tumour, and the rate of its growth within the body. Cancer diagnosis can be segmented into: imaging testing, endoscopy, biopsy and tumour marker. Each segment can be sub segmented.

The global cancer diagnostic market is expected to increase at a significant growth rate during the forecasted period (2016-2020). The global cancer diagnostic market is supported by various growth drivers, such as the rising incidence of cancer, sedentary lifestyle, growing technological advancement, increasing awareness, etc.

Table Of Content
 
1. Executive Summary

2. Introduction
2.1 Cancer Overview
2.2 Cancer Diagnostic: Overview
2.3 Cancer Diagnostic: Liquid Biopsy

3. Market Analysis

3.1 Cancer Prevalence Analysis
3.1.1 Global Cancer New Cases and Death
3.1.2 Global Cancer Prevalence, New Cases and Death by Type
3.1.3 US Cancer Prevalence
3.1.4 US Cancer New Cases and Death by Type

3.2 Cancer Diagnostic Market Analysis
3.2.1 Global Cancer Diagnostic Market by Value
3.2.2 Global Cancer Diagnostic Market by Segments (Type of Tests)
3.2.3 Global Cancer Diagnostic Market by Segments (Type of Cancer)
3.2.4 Global Cancer Diagnostic Market by Region
3.2.5 North America Cancer Diagnostic Market by Value

3.3 Lung Cancer Diagnostic Market Analysis
3.3.1 Global Lung Cancer Diagnostic Market by Value
3.3.2 Global Lung Cancer Diagnostic Market by Segment (Type of Test)
3.3.3 Global Lung Cancer Cases by Type

3.4 Breast Cancer Diagnostic Market Analysis
3.4.1 Global Breast Cancer Diagnostic Market by Value

3.5 MetaStat (Meta Test) Analysis (Breast Cancer Test)
3.5.1 Mena Testing: An Overview
3.5.2 Mena Breast Cancer Test Market Opportunity (US)
3.5.3 US Mena Test Market Opportunity
3.5.4 US Mena Test Market by Number of Test and Addressable Population

3.6 OncotypeDX (Breast Cancer Test)
3.6.1 OncotypeDX by Addressable Market

3.7 OncoCyte (Lung Cancer Test)
3.7.1 OncoCyte Test by Average Price and Revenue
3.7.2 OncoCyte Test by Test Volume and Market Penetration

3.8 Veracytes Test (Lung Cancer Test)
3.8.1 Veracytes Percepta Test Overview

3.9 Integrated Diagnostics, Inc. Test (Lung Cancer Test)
3.9.1 Integrated Diagnostics, Inc. Test Overview

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=841071

Global Breast Cancer Market Report: 2015 Edition | Now Available at Researchmoz.us

Researchmoz added Most up-to-date research on "Global Breast Cancer Market Report: 2015 Edition" to its huge collection of research reports.

Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women. Breast cancer knows no boundaries be it age, gender, socioeconomic status or geographic location. The most common risk factors for breast cancer are being female and growing older.

In the past few years, the cases of breast cancer have increased tremendously in regions like the US and the Europe. The breast cancer market is driven by various factors like aging female population, obesity and diabetes, dense breast tissues, healthcare expenditure, exposure to X-Ray and Gamma Radiations, Estrogen-Progestin Therapy (EPT) and increased consumption of alcohol and tobacco. A major trend which will probably remain eternally in the breast cancer treatment industry is the fact that novel and innovative technologies and pharmaceutical molecules are always under development. Challenges associated with breast cancer are like, financial burdens associated with the treatment and adverse effects of Aromatase Inhibitors (AI) on patients.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=315089

The market for breast cancer drugs represents an area of potential opportunity in both developed and developing countries. Due to effectiveness and advancements in technology, a large number of companies are focusing to develop innovative breast cancer drugs. Further, the companies are forming alliances and agreements to develop effective treatment methods for breast cancer.

The present report provides a comprehensive analysis of the global breast cancer diagnosis and treatment market with focus on regions like the US, Brazil, Europe and APAC Countries. Furthermore, market dynamics such as the industry trends and development, the underlying growth drivers and major issues faced by the industry are elicited. On the contention front, the market is personified by the intense competition in terms of research and development of novel therapeutic molecules. The leading players operating in the industry include Hologic, Johnson and Johnson, Siemens AG, Roche and Novartis which are also profiled in this report.

Table Of Content

1. Market Overview1.1 Breast Cancer
1.2 Types of Breast Cancer
1.3 Risk Factors
1.4 Symptoms of Breast Cancer
1.5 Diagnosis and Treatment of Breast Cancer
1.5.1 Breast Cancer Screening and Diagnostic Measures
1.5.2 Breast Cancer Treatment

2. Breast Cancer Market
2.1 Global Market

    Diagnostics Market
    Therapeutic Market
    Market Segmentation

3. Regional Markets
3.1 The U.S. Breast Cancer Market
3.1.1 The U.S. Breast Cancer Diagnostics Market
3.1.2 The U.S. Breast Cancer Therapeutic Market
3.1.3 The U.S. Metastatic Breast Cancer Market
3.2. Brazilian Breast Cancer Market
3.2.1 Brazilian Breast Cancer Diagnostic Market
3.2.2 Brazilian Breast Cancer Therapeutic Market
3.3 APAC Countries
3.3.1 APAC Diagnostic Market
3.3.2 APAC Therapeutic Market
3.4 European Breast Cancer Market
3.4.1 European Breast Cancer Diagnostic Market
3.4.2 European Metastatic Breast Cancer Market

4. Market Dynamics
4.1 Industry Developments
4.1.1 Introduction of New Drugs & Therapies
4.1.2 Development of Scintimammography for Molecular Breast Imaging
4.1.3 Compounds under Study to Reduce Breast Cancer
4.1.4 Researches on DCIS Prediction
4.2 Growth Drivers
4.2.1 Increasing Use of Tobacco and Alcohol
4.2.2 Increasing Diabetic and Obese Population Worldwide
4.2.3 Rising Healthcare Expenditure
4.2.4 Growing Women Population (Over 45 Years)
4.2.5 Increasing Global Spending on Medicines
4.2.6 Dense Breast Tissue
4.2.7 Exposure to X-Ray and Gamma Radiations
4.2.8 Estrogen-Progestin Therapy (EPT)
4.3 Challenges
4.3.1 Financial Burden of Breast Cancer
4.3.2 Adverse Effects of Aromatase Inhibitors (AI)

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=315089